Payment overview · 2025
General Payments
1 reported records · 1 companies
Healthcare provider profile · identity verified
Allopathic & Osteopathic Physicians|Family Medicine · STOCKTON, CA · NPI 1154387256
Verified facts
CMS Open Payments records show Michael Shi, MD received $21.61 in general payments during 2025 across 1 reported records.
Novo Nordisk Inc accounted for 100.0% of that reported general-payment amount.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
1 reported records · 1 companies
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.61 | 100.0% | 1 | 2025 |
What were the payments for?
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $21.61 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 604 | 95 |
| Atorvastatin Calcium | Atorvastatin Calcium | 393 | 134 |
| Losartan Potassium | Losartan Potassium | 313 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 233 | 71 |
| Alprazolam | Alprazolam | 202 | 38 |
| Metformin Hcl | Metformin Hcl | 202 | 56 |
| Omeprazole | Omeprazole | 202 | 51 |
| Alendronate Sodium | Alendronate Sodium | 201 | 59 |
| Gabapentin | Gabapentin | 177 | 43 |
| Lisinopril | Lisinopril | 150 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 141 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 135 | 40 |
| Dexamethasone | Dexamethasone | 135 | 101 |
| Fluoxetine Hcl | Fluoxetine Hcl | 113 | 20 |
| Simvastatin | Simvastatin | 113 | 34 |
| Trazodone Hcl | Trazodone Hcl | 107 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 97 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 96 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 91 | 24 |
| Lovastatin | Lovastatin | 89 | 24 |
| Furosemide | Furosemide | 86 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 83 | 22 |
| Ibuprofen | Ibuprofen | 82 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 78 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 25 |
| Allopurinol | Allopurinol | 73 | 21 |
| Cephalexin | Cephalexin | 71 | 48 |
| Donepezil Hcl | Donepezil Hcl | 70 | 16 |
| Azithromycin | Azithromycin | 69 | 53 |
| Atenolol | Atenolol | 64 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 64 | 24 |
| Famotidine | Famotidine | 62 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 61 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 60 | 13 |
| Tramadol Hcl | Tramadol Hcl | 59 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 25 |
| Trulicity | Dulaglutide | 53 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 24 |
| Jardiance | Empagliflozin | 50 | 15 |
| Glipizide Er | Glipizide | 46 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 13 |
| Glimepiride | Glimepiride | 44 | 14 |
| Lorazepam | Lorazepam | 44 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 44 | 11 |
| Potassium Chloride | Potassium Chloride | 44 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 15 |
| Diazepam | Diazepam | 42 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 16 |
| Nystatin | Nystatin | 40 | 17 |
| Montelukast Sodium | Montelukast Sodium | 37 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 25 |
| Meloxicam | Meloxicam | 36 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 29 |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Glipizide | Glipizide | 34 | suppressed |
| Risperidone | Risperidone | 33 | suppressed |
| Carvedilol | Carvedilol | 32 | 14 |
| Finasteride | Finasteride | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | suppressed |
| Pregabalin | Pregabalin | 30 | suppressed |
| Naproxen | Naproxen | 29 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Eliquis | Apixaban | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 26 | suppressed |
| Baclofen | Baclofen | 24 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | 13 |
| Bumetanide | Bumetanide | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 21 | suppressed |
| Carisoprodol | Carisoprodol | 20 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Clotrimazole | Clotrimazole | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Ozempic | Semaglutide | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 13 | 13 |
| Prednisone | Prednisone | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Clonazepam | Clonazepam | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $21.61 · 1 records | Novo Nordisk Inc | — | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error